Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020
SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on May 29, 2020. The poster presentation will show interim data for HPN424 from its ongoing dose escalation Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). HPN424 targets prostate-specific membrane antigen (PSMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to target and kill tumor cells.
Full details of the presentation are as follows:
Abstract/Poster Title: First-in-human, Phase 1 study of HPN424, a tri-specific half-life extended PSMA-targeting T cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: Johanna Bendell, M.D., et al.
Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Date and Time: May 29, available on demand beginning at 8 a.m. ET
Abstract / Poster Number: 5552 / 133
Location: ASCO Meeting Library at https://meetinglibrary.asco.org/record/187904/abstract
A copy of the presentation will be available on the company’s website at https://ir.harpoontx.com/events-and-presentations.
Conference Call and Webcast
Harpoon’s management will host a webcast and conference call at 4 p.m. ET / 1 p.m. ET on Friday, May 29, 2020 to review the data and provide an update on other pipeline programs. The live call may be accessed by dialing:
877-407-9716 for domestic callers
201-493-6779 for international callers
A live webcast of the call will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the live event.
About the Phase 1 Clinical Trial for HPN424
This Phase 1 trial is a multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics and activity of HPN424 in patients with mCRPC who are progressing. The trial is titled, “A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy.” For additional information about the trial, please visit www.clinicaltrials.gov using the identifier NCT03577028.
The initial phase of the trial is a dose escalation phase, with the goal of determining a recommended dose for the expansion phase of the trial. HPN424 is being administered to patients once weekly by intravenous infusion. The primary outcome measures are an assessment of safety and tolerability, pharmacokinetics, and determination of a dose for the expansion phase of the trial. Secondary endpoints include overall response rate, progression free and overall survival, and duration of response. The expansion portion of the trial will further evaluate the safety and activity of HPN424 in patients with mCRPC.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1 trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin including ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is planned for initiation of a Phase1/2 trial for small cell lung cancer and other tumors. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, and the timing of development milestones for product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Harpoon Therapeutics, Inc.
Chief Financial Officer
Robert H. Uhl